

Please type a plus sign (+) inside this box →



*3/28/04*

Substitute for form 1449A/B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	Unassigned 10808272
Filing Date	March 23, 2004
First Named Inventor	Joseph A. HRABIE
Group Art Unit	Unassigned 1624
Examiner Name	Unassigned PATEL
Attorney Docket Number	227957

Sheet 1 of 1

## U.S. PATENT DOCUMENTS

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
<i>SA</i>	AA	4,954,526	US	Keefer	09-04-90	—
<i>SA</i>	AB	5,155,137	US	Keefer et al.	10-13-92	—
<i>SA</i>	AC	5,212,204	US	Keefer et al.	05-18-93	—

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
<i>SA</i>	AD	WO	93/13055		Wellcome Found.	07-08-93	—	—
<i>SA</i>	AE	WO	94/27957		Univ. California	12-08-94	—	—
<i>SA</i>	AF	WO	95/05363		Fisons Corp.	02-23-95	—	—
<i>SA</i>	AG	WO	96/40665		Gov. of U.S.	12-19-96	—	—
<i>SA</i>	AH	DD	122,080		Ohme et al.	09-12-76	—	—

## OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
<i>SA</i>	AI	BOGDAN C., PubMed Abstract 11577346, also cited as <i>Nat. Immunol.</i> , 2(10), 907-916 (2001)	—	—
	AJ	CHABRIER et al., PubMed Abstract 10442086, also cited as <i>Cell. Mol. Life Sci.</i> , 55(8-9), 1029-1035 (1999)	—	—
	AK	Derwent Abstract AN-85-047728, Derwent Publications Ltd., "New N, N'-dihydroxydiazonium Propanol Derivative for Prevention and Treatment of Apple Canker" (January 14, 1985)	—	—
	AL	FELDMAN et al., <i>C&amp;EN</i> , 26-38 (1993)	—	—
	AM	FREEMAN et al., "Alkaline Decomposition of Nitrosohydroxylamine Derivatives," <i>J. Org. Chem.</i> , 35(9), 3107-3110 (1970)	—	—
	AN	LE CORVOISER et al., PubMed Abstract 11324316, also cited as <i>J. Soc. Biol.</i> , 194(3-4), 143-149 (2000)	—	—
	AO	NATHAN C., <i>FASEB</i> , 6, 3051-3063 (1993)	—	—
	AP	OKA et al., PubMed Abstract 12909236, also cited as <i>Int. J. Radiat. Oncol. Biol. Phys.</i> , 57(1), 217-221 (2003)	—	—
	AQ	TURUNEN et al., PubMed Abstract 10817812, also cited as <i>Exp. Gerontol.</i> , 34(4), 567-574 (1999)	—	—
<i>SA</i>	AR	VOLODARSKII et al., "Preparation and Properties of N-nitroso-alpha-hydroxylamino Oximes," <i>Chemical Abstracts</i> , 85(21), abstract no. 15959w (1976)	—	—
<i>SA</i>	AS	WANG et al., PubMed Abstract 12856639, also cited as <i>Urol. Oncol.</i> , 21(2), 117-122 (2003)	—	—

Examiner Signature

*Joseph A. HRABIE*


Date Considered

8/12/04

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

+



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	1	of	1
-------	---	----	---

Application Number	10/349,228
Filing Date	January 22, 2003
First Named Inventor	Joseph A. HRABIE
Group Art Unit	1624
Examiner Name	Sudhaker B. Patel
Attorney Docket Number	220914

[illegible][illegible][illegible]

Wald by W. B. C.

81202

- \* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).